1-year controlled trial of 1 alpha-hydroxycholecalciferol in patients on maintenance hemodialysis.
A 1-year controlled trial was performed to confirm the effects of 1 alpha-hydroxycholecalciferol (1 alpha-OH-D3) in chronic hemodialysis patients. Initially, a daily dose of 2 micrograms of 1 alpha-OH-D3 was given orally to 24 patients and its placebo to another 24 patients during the first 3 months. For the following 9 months the dose of 1 alpha-OH-D3 or its placebo was reduced to 1 microgram per day in the individual groups. Serum calcium was significantly increased to the normal level after 1 month of treatment and sustained at this level for 1 year. Serum parathyroid hormone was significantly decreased at 3 months. Serum alkaline phosphatase was decreased to the normal level at the 5th month and thereafter. At 2 months serum phosphorus was significantly increased in the 1 alpha-OH-D3 group. None of the patients on 1 alpha-OH-D3 showed increased subperiosteal resorption on X-rays, whereas 8 out of 20 patients on placebo did (p less than 0.002). No adverse effects were seen apart from 3 patients with the 'red eye' of scleral calcification.
D000469:Alkaline Phosphatase / Q000097:blood; D001862:Bone Resorption; D002118:Calcium / Q000097:blood; D002986:Clinical Trials as Topic; D005260:Female; D006225:Hand / Q000000981:diagnostic imaging; D006801:Humans; D006887:Hydroxycholecalciferols / Q000494:pharmacology*; D007676:Kidney Failure, Chronic / Q000097:blood / Q000628:therapy; D008297:Male; D010281:Parathyroid Hormone / Q000097:blood; D010758:Phosphorus / Q000097:blood; D010919:Placebos; D011859:Radiography; D006435:Renal Dialysis
D006887:Hydroxycholecalciferols; D010281:Parathyroid Hormone; D010919:Placebos; D010758:Phosphorus; D000469:Alkaline Phosphatase; D002118:Calcium; C008088:alfacalcidol